Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1986 2
1988 2
1992 1
1993 1
1995 2
1996 1
1999 1
2000 3
2001 2
2002 1
2003 2
2004 2
2005 5
2006 2
2007 2
2008 3
2009 8
2010 7
2011 4
2012 4
2013 3
2014 4
2015 11
2016 8
2017 2
2018 3
2019 5
2020 1
2021 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Evolving therapies for myocardial ischemia/reperfusion injury.
Ibáñez B, Heusch G, Ovize M, Van de Werf F. Ibáñez B, et al. Among authors: van de werf f. J Am Coll Cardiol. 2015 Apr 14;65(14):1454-71. doi: 10.1016/j.jacc.2015.02.032. J Am Coll Cardiol. 2015. PMID: 25857912 Free article. Review.
The remarkable reduction in death rates achieved with these therapies has resulted in a shift in emphasis from efforts to reduce mortality to a focus on tackling the downstream consequence of survival: post-infarction heart failure. Infarct size is the main determinant of long- …
The remarkable reduction in death rates achieved with these therapies has resulted in a shift in emphasis from efforts to reduce mortality t …
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. Among authors: van de werf f. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. ...
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibit …
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee. CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3. Lancet. 1996. PMID: 8918275 Clinical Trial.
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. ...There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L …
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical t …
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), et al. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. Eur Heart J. 2012. PMID: 22922416 Free article. No abstract available.
Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry.
Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, Tendera M, Laroche C, Maggioni AP, Baban A, Khraiche D, Ziolkowska L, Limongelli G, Ojala T, Gorenflo M, Anastasakis A, Mostafa S, Caforio ALP; EORP Paediatric Cardiomyopathy Registry Investigators. Kaski JP, et al. Eur Heart J. 2024 Apr 21;45(16):1443-1454. doi: 10.1093/eurheartj/ehae109. Eur Heart J. 2024. PMID: 38427064
METHODS: Prospective data were collected on individuals aged 1-<18 years enrolled in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry (June 2014-December 2016). RESULTS: A total of 633 individuals a …
METHODS: Prospective data were collected on individuals aged 1-<18 years enrolled in the European Society of Cardiology EURObservational …
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Van de Werf F. Van de Werf F. Nat Rev Cardiol. 2014 Nov;11(11):624-5. doi: 10.1038/nrcardio.2014.129. Epub 2014 Sep 2. Nat Rev Cardiol. 2014. PMID: 25178500 Review.
Despite these successes, however, renewed efforts are needed to improve long-term outcomes after ACS by reducing recurrent ischaemic events and lowering the risk of bleeding complications....
Despite these successes, however, renewed efforts are needed to improve long-term outcomes after ACS by reducing recurrent ischaemic …
Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes.
Martín-Asenjo R, Gregson J, Rossello X, Van de Werf F, Medina J, Danchin N, Pocock S, Bueno H. Martín-Asenjo R, et al. Among authors: van de werf f. J Cardiovasc Transl Res. 2021 Aug;14(4):790-798. doi: 10.1007/s12265-020-10094-5. Epub 2021 Jan 8. J Cardiovasc Transl Res. 2021. PMID: 33420682
The number of antithrombotic drugs (excluding oral anticoagulants) used pre- and in-hospital was recorded in ACS survivors enrolled at hospital discharge in the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry …
The number of antithrombotic drugs (excluding oral anticoagulants) used pre- and in-hospital was recorded in ACS survivors enrolled at hospi …
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.
Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Bergmark BA, et al. Among authors: van de werf fj. J Am Heart Assoc. 2021 Sep 7;10(17):e020446. doi: 10.1161/JAHA.120.020446. Epub 2021 Aug 21. J Am Heart Assoc. 2021. PMID: 34423649 Free PMC article. Clinical Trial.
Background Coronary stent type and risk of stent thrombosis remain important factors affecting recommended duration of dual antiplatelet therapy. We investigated the efficacy and safety of long-term ticagrelor in patients with prior coronary stenting enrolled in the PEGASU …
Background Coronary stent type and risk of stent thrombosis remain important factors affecting recommended duration of dual antiplatelet the …
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, Moliterno DJ, Mahaffey KW, Tricoci P. Hess PL, et al. Among authors: van de werf f. JAMA Cardiol. 2016 Apr 1;1(1):73-9. doi: 10.1001/jamacardio.2015.0359. JAMA Cardiol. 2016. PMID: 27437658
OBJECTIVE: To determine the cumulative incidence of SCD during long-term follow-up after NSTE ACS, to develop a risk model and risk score for SCD after NSTE ACS, and to assess the association between recurrent events after the initial ACS presentation and the risk for SCD. …
OBJECTIVE: To determine the cumulative incidence of SCD during long-term follow-up after NSTE ACS, to develop a risk model and risk s …
84 results